Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 5/20 | 0.57 |
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | JAK3 | P52333 | 5/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.52 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183390 | 0.88 | JAK3 (0.57) | JAK1JAK2JAK3PIK3CDPIK3CA | |
| SCHEMBL20183351 | 0.85 | JAK1 (0.55) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL28345574 | 0.83 | JAK1 (0.70) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL30208811 | 0.80 | JAK3 (0.69) | JAK1JAK2JAK3 | |
| SCHEMBL16765396 | 0.80 | JAK3 (0.69) | JAK1JAK2JAK3 | |
| SCHEMBL14697253 | 0.80 | JAK3 (0.62) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL16765395 | 0.80 | JAK3 (0.69) | JAK1JAK2JAK3 | |
| SCHEMBL18419749 | 0.79 | JAK1 (0.55) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13960903 | 0.79 | JAK3 (0.60) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL15856585 | 0.79 | JAK3 (0.51) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | JAK1 120/4885JAK2 127/4885JAK3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.